BioPharma CEOs Issue COVID-19 Vaccine Pledge
Sept. 8, 2020
The CEOs of nine major biopharmaceutical firms today issued a pledge to continue to make the safety and well-being of vaccinated individuals the top priority in the development of the first COVID-19 vaccines, saying they are committed to uphold the integrity of the scientific processes. In part, their statement reads:
“Following guidance from expert regulatory authorities such as FDA regarding the development of COVID-19 vaccines, consistent with existing standards and practices, and in the interest of public health, we pledge to:
- Always make the safety and well-being of vaccinated individuals our top priority.
- Continue to adhere to high scientific and ethical standards regarding the conduct of clinical trials and the rigor of manufacturing processes.·
- Only submit for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA.·
- Work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.
We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved.”